Search Results
3 Results Found for “Burosumab”
New data presented at ENDO 2026 highlighted the continued evolution of endocrine care, with studies spanning rare disease management, long-term hormone replacement, artificial intelligence-supported screening and real-world treatment outcomes. Across several presentations, investigators reported sustained improvements in biochemical, metabolic, skeletal and patient-reported outcomes, while also emphasising the importance of long-term follow-up and careful interpretation of emerging data.
Welcome to the summer 2026 issue of touchREVIEWS in Endocrinology. In this issue, we bring together articles that reflect the evolving complexity of endocrine and metabolic disease, while highlighting the growing importance of patient-centred care, translational science and interdisciplinary management. We ...
Pathophysiology of X-linked hypophosphataemia X-linked hypophosphataemia (XLH) is a progressive skeletal disorder, originally defined by Albright in 1937 as hypophosphataemic vitamin D rickets.1Â XLH is the commonest form of inherited rickets/osteomalacia and is an X-linked dominant condition.2Â The most common ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
